Spots Global Cancer Trial Database for volasertib
Every month we try and update this database with for volasertib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Investigation of Potential Drug-drug Interaction of Volasertib With Itraconazole in Patients With Various Tumours | NCT01772563 | Neoplasms | volasertib itraconazole | 18 Years - 70 Years | Boehringer Ingelheim | |
| Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | NCT02861040 | Recurrent Adult... Refractory Adul... | Laboratory Biom... Pharmacological... Vincristine Sul... Volasertib | 18 Years - | Northwestern University | |
| Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | NCT02201329 | Myelodysplastic... Leukemia, Myelo... | Azacitidine Volasertib | 20 Years - 80 Years | Boehringer Ingelheim | |
| Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas | NCT02875002 | Relapsed and Re... Lymphoma | volasertib belinostat | 18 Years - | Yale University | |
| Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes | NCT02721875 | Myelodysplastic... | Volasertib Volasertib Azacitidine | 18 Years - | Boehringer Ingelheim | |
| Investigation of Potential Drug-drug Interaction of Volasertib With Itraconazole in Patients With Various Tumours | NCT01772563 | Neoplasms | volasertib itraconazole | 18 Years - 70 Years | Boehringer Ingelheim | |
| Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML | NCT01957644 | Myelodysplastic... Leukemia, Myelo... | Azacitidine Volasertib | 18 Years - | Boehringer Ingelheim | |
| Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | NCT02861040 | Recurrent Adult... Refractory Adul... | Laboratory Biom... Pharmacological... Vincristine Sul... Volasertib | 18 Years - | Northwestern University | |
| Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known | NCT01971476 | Leukemia Neoplasms | volasertib | 2 Years - 17 Years | Boehringer Ingelheim | |
| Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia | NCT02905994 | AML | Volasertib Cytarabine Idarubicin Bone Marrow Bio... | 18 Years - | Massachusetts General Hospital | |
| A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed | NCT02722135 | Leukemia, Myelo... | Volasertib | 3 Months - 17 Years | Boehringer Ingelheim | |
| Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | NCT02198482 | Acute Myeloid L... High-risk Myelo... | Volasertib Cytarabine Daunorubicin Mitoxantrone | 18 Years - | University of Ulm | |
| A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia | NCT02527174 | Leukemia, Myelo... Leukemia, Monoc... Leukemia, Myelo... Leukemia, Eryth... Leukemia, Megak... | Volasertib Idarubicin Cytarabine | 18 Years - 75 Years | University of Alberta | |
| Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2) | NCT01721876 | Leukemia, Myelo... | Placebo Volasertib Cytarabine | 65 Years - | Boehringer Ingelheim | |
| Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML) | NCT01662505 | Leukemia, Myelo... | Volasertib | 18 Years - 99 Years | Boehringer Ingelheim | |
| Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | NCT02201329 | Myelodysplastic... Leukemia, Myelo... | Azacitidine Volasertib | 20 Years - 80 Years | Boehringer Ingelheim | |
| Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes | NCT02721875 | Myelodysplastic... | Volasertib Volasertib Azacitidine | 18 Years - | Boehringer Ingelheim | |
| Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML | NCT01957644 | Myelodysplastic... Leukemia, Myelo... | Azacitidine Volasertib | 18 Years - | Boehringer Ingelheim | |
| Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes | NCT02721875 | Myelodysplastic... | Volasertib Volasertib Azacitidine | 18 Years - | Boehringer Ingelheim | |
| Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | NCT02201329 | Myelodysplastic... Leukemia, Myelo... | Azacitidine Volasertib | 20 Years - 80 Years | Boehringer Ingelheim | |
| Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML) | NCT01662505 | Leukemia, Myelo... | Volasertib | 18 Years - 99 Years | Boehringer Ingelheim | |
| Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia | NCT00804856 | Leukemia, Myelo... | Volasertib Cytarabine | 18 Years - | Boehringer Ingelheim |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
